This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.

The deal gives Mirum access to Bluejay’s monoclonal antibody brelovitug, which is currently in Phase III trials.

The bipolar disorder (BD) market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and ...

Inductive Bio has secured up to $21m in funding from ARPA-H to lead the development of AI drug-toxicity prediction models.

Roche has received EC approval for its humanised monoclonal antibody Gazyva, in combination with mycophenolate mofetil (MMF).

If approved, Regeneron and Tessera's TSRA-196 could become the first curative therapy to reach patients with AATD, who have ...

Takeda and Innovent have closed their global partnership for next-generation IO and ADC therapies after fulfilment of ...

Agilent Technologies has expanded its collaboration with Monash University Malaysia (MUM) for the establishment of a ...

Viatris has signed definitive agreements for the sale of its equity stake in Biocon Biologics to Biocon for $815m.

Høeg’s appointment to director of the FDA's CDER follows a turbulent period for the department, which has seen five leaders ...

The UK becomes the latest country in President Donald Trump’s long line of trade agreements, though it is the first region to ...

On 1 December, the fortunes of the UK pharma sector changed radically, with the UK Government becoming the first in the world ...